In brief
McKinsey has agreed to pay $650 million to settle charges regarding its involvement in the opioid crisis. This outcome follows its partnership with Purdue Pharma to boost OxyContin sales while obscuring its risks. The firm acknowledged its role in the crisis, which has caused significant addiction and overdose deaths in America.
Consulting firm McKinsey has made headlines by agreeing to a $650 million settlement regarding its involvement in the opioid crisis in the United States. The company's actions included a conspiracy with Purdue Pharma, where they helped misbrand prescription drugs without valid prescriptions. According to the US Department of Justice, McKinsey "knowingly and intentionally" aided in the drug's misbranding, contributing to the ongoing opioid epidemic. In a statement, McKinsey recognized the harm caused by opioids, saying, "we should have appreciated the harm opioids were causing in our society." As part of the settlement, former senior partner Martin Elling plans to plead guilty to obstruction for destroying crucial records connected to the case. McKinsey's deferred prosecution agreement means the charges may be dismissed in five years, assuming the company meets specified conditions for reform.This isn't McKinsey's first financial commitment related to opioids; the firm previously settled nearly $1 billion from lawsuits linked to its operations with Purdue and other pharmaceutical entities. Purdue Pharma, on its end, had its own legal troubles, with a guilty plea in 2020 leading to an $8.3 billion settlement for its role in promoting OxyContin and enabling its distribution without legitimate medical purpose.The opioid crisis has had devastating consequences, with nearly 100,000 drug overdose deaths reported annually in the U.S. While recent data shows a slight drop in overdose deaths, the legacy of opioid addiction continues to affect families and communities.
